生物制药公司Summit Therapeutics（SMMT）今日盘前大涨5.15%，引起投资者关注。尽管公司最新季报显示亏损扩大，但分析师对其前景持乐观态度。
根据公司发布的截至2025年3月31日的季度财报，Summit Therapeutics当季每股亏损45美分，远低于分析师预期的9美分亏损，也显著高于去年同期6美分的亏损。公司当季净亏损达6290万美元，收入为零。尽管财务表现不佳，但公司股价本季度仍上涨了25.0%，今年迄今为止已上涨35.2%。
值得注意的是，尽管业绩不佳，分析师仍对Summit Therapeutics保持乐观态度。目前，分析师对该公司股票的平均评级为"买入"，其中9个为"强烈买入"或"买入"评级，没有"持有"、"卖出"或"强烈卖出"评级。华尔街对Summit Therapeutics未来12个月的目标价中位数为36.00美元，远高于当前股价。这种积极的分析师评级可能是推动股价上涨的主要因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.